



OREGA Biotech's interleukin-17 patent to be granted in the US

Receipt of a Notice of Allowance from USPTO
for a strategic patent application related to OREGA's IL-17 program

Lyon, France, April 18, 2017 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification of allowance from the USPTO stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers antibodies binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. The related European Patent has already been granted in 2016.

"The delivery of this US Patent is a significant milestone for OREGA Biotech's IL-17 program. Our business model relies on our ability to discover novel targets and to generate IP rights over targets or broad claims such as functional epitopes", commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech.

As of today, the patent portfolio of the company is composed of 9 families of patent applications owned or co-owned by OREGA biotech.

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. With a specific focus on tumor microenvironment, OREGA's Target Discovery Program aims at discovering and validating novel clinically-relevant cancer targets.

Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. OREGA's business strategy is to bring its R&D programs up to preclinical proof of concept, IND or early clinical stages and then to license them out to larger biotech or pharmaceutical companies. Funded by initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative, the company is managed by Gilles Alberici, CEO and Jeremy Bastid, COO.

Contact

Jeremy Bastid, Chief Operating Officer
Tel.: +33 (0)4 37 49 87 20
jeremy.bastid@orega-biotech.com

For more information: www.orega-biotech.com